← All trials
NCT03118674
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- May 20, 2017
- Primary completion
- Aug 30, 2022
- Completion date
- Aug 30, 2022
- First posted
- —
- Last posted
- —
- Enrollment
- 49
- Arms / groups
- 1 / —
- Source
- AACT · pre-existing
Sponsors
- Wake Forest UniversityLead sponsor
- Wake Forest UniversityStudy chair
- Gilead SciencesCollaborator
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Collaborator
- Wake Forest UniversityReponsible party - principal investigator
- National Institutes of Health (NIH)Collaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.